Corcept Therapeutics Balances Growth With Rising Risks

Corcept Therapeutics ((CORT)) has held its Q4 earnings call. Read on for the main highlights of the call.

Corcept Therapeutics’ latest earnings call blended strong commercial momentum and clinical wins with sharp regulatory and legal headwinds. Management highlighted accelerating demand for its Cushing’s franchise and a deep pipeline with multiple near‑term catalysts, even as a Cushing’s regulatory setback, patent loss, and weaker profitability tempered investor enthusiasm.

Revenue Growth and 2026 Guidance

Corcept reported 2025 revenue of $761 million, up about 12.8% from $675 million a year earlier, underscoring resilient demand in its core endocrinology business. Management raised the stakes for 2026, guiding to $900 million to $1 billion in revenue, signaling confidence that growth can continue despite mounting competition and pricing pressure.

Strong Cash Position and Capital Actions

The company closed 2025 with $532 million in cash and investments, providing substantial flexibility to fund R&D and navigate legal and regulatory battles. Corcept also returned capital to shareholders, repurchasing $245 million of stock during the year under its ongoing buyback program.

Commercial Demand Expansion for Cushing’s Products

New prescriptions for the company’s Cushing’s therapies surged 61% in 2025, highlighting both increased physician adoption and expanded patient reach. Despite capacity constraints, tablets delivered still climbed 37% and monthly new patient starts improved as the year progressed.

CATALYST Trial — Diabetes Population Findings

In the CATALYST study, Corcept screened 1,000 patients with uncontrolled diabetes and found that 24% had underlying hypercortisolism, underscoring a potentially underdiagnosed market. Among 136 randomized patients, Korlym cut mean HbA1c by 1.47% versus 0.17% on placebo, with meaningful reductions in weight and waist circumference.

ROSELLA Phase III — Positive Oncology Outcomes

In the ROSELLA Phase III trial in platinum‑resistant ovarian cancer, relacorilant plus nab‑paclitaxel reduced the risk of death by 35% versus control, with a hazard ratio of 0.65 and strong statistical significance. Median overall survival improved by 4.1 months, and patients at the 75th percentile lived up to eight months longer, with full data headed to a major oncology meeting.

DAZALS (ALS) Phase II — Large Mortality Signal

The DAZALS Phase II trial in ALS produced an eye‑catching mortality benefit, with patients on 300 mg dazucorilant over one year showing an 84% lower risk of death versus placebo. Corcept is now doing dose‑titration work to improve tolerability and plans to move the program into a pivotal trial later this year.

Ongoing Pipeline Momentum and Upcoming Readouts

Beyond oncology and ALS, Corcept’s pipeline is broadening with metabolic and cardiovascular opportunities, including the fully enrolled MONARCH Phase IIb MASH trial with results expected by year‑end. The company also flagged upcoming MOMENTUM data in resistant hypertension and a string of oncology and combination readouts expected through 2027.

Resolved Pharmacy Capacity Transition

Operationally, Corcept has completed its transition to new specialty pharmacy partner Curant, resolving prior bottlenecks that limited product delivery. Management said fulfillment metrics are improving, all patient files have moved over, and February is tracking toward a record month for new patient starts.

FDA Complete Response Letter for Relacorilant in Cushing’s Syndrome

On the downside, the FDA issued a complete response letter for relacorilant in Cushing’s syndrome, even though the GRACE study met its primary endpoint with statistical significance. Regulators raised concerns including liver enzyme elevations, and Corcept now plans to meet with the agency to determine whether to pursue resubmission, appeal, or additional clinical work.

Federal Circuit Ruling Against Patent Case Versus Teva

Legal risk also moved to the forefront after the Federal Circuit ruled against Corcept in its effort to block Teva from marketing a generic version of Korlym. The company argues the court erred and intends to appeal, but the decision increases the potential for generic competition to pressure its key Cushing’s revenue stream.

Net Income Decline

Despite higher sales, profitability stepped back, with 2025 net income falling to $99.7 million from $141.2 million in 2024, a drop of roughly 29%. The decline reflects higher costs, legal and development spending, and growing pricing headwinds in the Cushing’s franchise.

Commercial Supply Disruption Impacted Deliveries

Earlier in the year, capacity constraints at the prior pharmacy partner caused a mismatch between surging demand and actual product shipped, with new prescriptions up 61% but tablets delivered up only 37%. Management acknowledged that some prescriptions were delayed or lost during the transition, but expects the issue to be behind them with the new vendor.

Authorized Generic Price Pressure

By year‑end, about 75% of Corcept’s Cushing’s volume flowed through its authorized generic channel, rising to roughly 78% currently, at an approximate 30% discount to list price. The company believes the associated pricing pressure has largely stabilized, and these lower net prices are now baked into its 2026 revenue assumptions.

Tolerability Issues in DAZALS Leading to Discontinuations

In DAZALS, the standout survival benefit came with a trade‑off in gastrointestinal tolerability, which drove most treatment discontinuations despite events being nonserious. Corcept hopes a dose‑titration strategy will preserve efficacy while reducing GI distress, a key step before launching a pivotal ALS program.

Forward‑Looking Outlook and Guidance

Management’s 2026 revenue guidance of $900 million to $1 billion rests mainly on continued expansion of the Cushing’s business, with oncology still a smaller contributor near term. With $532 million in cash after heavy buybacks, an upcoming oncology regulatory decision, multiple late‑stage readouts, and a long‑term goal of at least $2 billion in annual Cushing’s revenue by decade’s end, the company is positioning for significant upside if it can navigate regulatory and generic risks.

Corcept’s earnings call painted a story of solid top‑line growth, accelerating prescription demand, and a pipeline that is starting to deliver high‑impact clinical signals across oncology, ALS, and metabolic disease. Investors will now focus on how the company manages its Cushing’s regulatory setback, looming generic competition, and profitability while trying to convert its rich set of clinical catalysts into durable, diversified revenue streams.